Last €12.58 EUR
Change Today +0.58 / 4.83%
Volume 105.6K
ALCLS On Other Exchanges
EN Paris
As of 11:35 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/14 - €14.58
52 Week Low
12/17/13 - €2.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, together with its subsidiaries, operates as a genome engineering company in France and internationally. The company designs and markets meganucleases and TALENs, which are tools that enable targeted modifications to DNA in the research, biomanufacturing, agro biotechnology, and therapeutic sectors; and develops and markets genome customization products used to create stable and isogenic cell lines with various characteristics and performances for use in the drug development, gene function studies, and protein production sectors. It also develops nucleases for various therapeutic applications, including correction of a genetic defect in the patient’s genome; destruction of viral genomes; or inactivation of genes to create cells with modified characteristics in the fields of cancer, viral infections, and genetic diseases. In addition, the company focuses on plant genome modification using nucleases that recognize specific DNA sequences to develop species with traits of value; and development of stem cell technology for controlling stem cell production and differentiation. It has strategic partnership agreement with Les Laboratoires Servier to develop and commercialize product candidates targeting leukemia and solid tumors. Cellectis was founded in 1999 and is based in Paris, France.

193 Employees
Last Reported Date: 04/30/14
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cellectis (ALCLS) Key Developments

Cellectis expected to report First-Half, 2014 results on July 29, 2014. This event was calculated by Capital IQ (Created on July 23, 2014).

Cellectis expected to report First-Half, 2014 results on July 29, 2014. This event was calculated by Capital IQ (Created on July 23, 2014).

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA

Cellectis announced it received a Scientific recommendation from the European Medicines Agency (EMA), in consultation with the European Commission, for UCART19, its lead product candidate in adoptive immunotherapy against CD19 expressing leukemias and lymphomas. UCART19 fulfills the definition of an Advanced-Therapy medicinal Product (ATmP) being eligible for Scientific Advices and Assessment from the EMA Committee for Advanced Therapies (CAT) as well as for European centralized Marketing Authorization Approval. The EMA/CAT considers that Cellectis' allogeneic engineered Chimeric Antigen Receptor (CAR+) T-cells fall within the definition of a Gene Therapy Medicinal Product.

Cellectis Presents at Piper Jaffray GenomeRx Symposium, Jun-23-2014

Cellectis Presents at Piper Jaffray GenomeRx Symposium, Jun-23-2014 . Venue: Yale Club, New York, New York, United States. Speakers: David J. D. Sourdive, Co-Founder, Head of the Treat Yourself Better Initiative, Executive Vice President of Corporate Development, Director and President of Ectycell.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €12.58 EUR +0.58

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellular Dynamics International Inc $11.85 USD -0.06
General Electric Co $25.45 USD -0.14
Lonza Group AG SFr.101.90 CHF 0.00
Sigma-Aldrich Corp $103.25 USD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 49.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at